|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61P 25/00 | |
| A61P 35/00 | |||
| A61K 31/565 | |||
| A61K 38/17 | |||
| A61K 31/64 | |||
| A61K 31/44 | |||
| A61K 31/40 | |||
| A61K 31/549 | |||
| A61K 31/175 |
| (11) | Number of the document | 2382977 |
| (13) | Kind of document | T |
| (96) | European patent application number | 10010752.3 |
| Date of filing the European patent application | 2005-09-16 | |
| (97) | Date of publication of the European application | 2011-11-02 |
| (45) | Date of publication and mention of the grant of the patent | 2014-08-06 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 610758 P | 2004-09-18 | US | |
| 698272 P | 2005-07-11 | US |
| (72) |
Simard, Marc J., US
|
| (73) |
University of Maryland, Baltimore,
Office of Research and Development 620 W. Lexington Street, 4th Floor, Baltimore, MD 21201,
US
The United States of America, as represented by the Department of Veterans Affairs, Department of Veterans Affairs Office of General Counsel - PSG IV (024) 810 Vermont Ave. N.W., Washington, DC 20420, US |
| (54) | Therapeutic agents targeting the ncca-atp channel and methods of use thereof |
| Therapeutic agents targeting the ncca-atp channel and methods of use thereof |